Cannabinoids (CBD and THC) Pipeline Drugs: Pipeline Analysis and Opportunity Assessment, H2 2021

GervanoRA's pipeline analysis and opportunity assessment report "Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2020" analyzed and assessed Cannabidiol pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cannabidiol Drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• ⚫ Unmet needs and Opportunities
• ⚫ Epidemiology and Epidemiology forecast 2019 - 2025
• ⚫ Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• ⚫ Patent Analysis of Pipeline Molecules
• ⚫ Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• ⚫ Clinical Trials Summary
• ⚫ Current and Future Competitive Landscape
• ⚫ Emerging Company Profiles with Opportunity Assessments
• ⚫ Pipeline Drug Descriptions along with Development milestones (Past and Future)
• ⚫ University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.